Longitudinal EvAluation of Symptom Burden in Hemodialysis Patient (LEASH)

Jodie Ford, B.Sc.(Pharm), B.Sc.(Agr); Marianna Leung, B.Sc.(Pharm), ACPR, PharmD; Beverly Jung, MD; Fong Huynh, B.Sc.(Pharm), ACPR, PharmD; Tinnie Chung, B.Sc.(Pharm), ACPR; Stan Marchuk, NP; Mercedeh Kiaii, MD; Clifford Chan-Yan, MD; Rob Werb, MD; Monica Beaulieu, MD

Background

- Hemodialysis (HD) patients have an extremely high symptom burden associated with their end-stage renal disease (ESRD), its complications and other comorbidities.
- Symptom burden in HD patients has been historically underrecognized and under-appreciated.
- The link between health-related quality of life and increased morbidity and mortality in ESRD patients is well established.
- Beginning in September 2010, nurses on the HD Unit at St. Paul's Hospital (SPH) assess patients quarterly for symptom burden using a validated modified Edmonton Symptom Assessment System (ESAS) questionnaire, evaluating 11 symptoms over time.
- Patients with a high symptom burden and severe scores for pain, insomnia, itchiness, depression and anxiety are reviewed regularly at rounds for targeted therapy.
- As part of a continuous quality improvement initiative, the purpose of this study is to evaluate the impact of systematic assessment and management in this cohort of HD patients.


Objectives

To compare ESAS symptom scores in matched HD patients at baseline and at one year in terms of:

- Severity: Mean score of each ESAS symptom
- Prevalence: Percentage of patients reporting severe ESAS symptoms (defined as 7 to 10 on a scale of 0 to 10)

Methods


- Design: retrospective cohort study
- Sample: HD patients at SPH, Providence Health Care
- Survey Tool: modified ESAS questionnaire (Figure 2)
- Inclusion: Patients who were 19 years of age and older
- Exclusion: Patients who were unable to complete the ESAS in English, Chinese, Punjabi or via an interpreter or caregiver
- Analysis: Symptom scores for patients who had completed 2 ESAS questionnaires in September 2010 and August 2011 were tabulated.
 Mean scores were compared using paired t-test while prevalence of severe symptoms were analyzed using McNemar's test





Age (years; median [IQR])	74 [62-80]
Male (%)	56%
Ethnicity (%) Caucasian Oriental Asian South Asian	25% 49% 9%
Dialysis Vintage (months; median [IQR])	35 [15-64]
Comorbidity (%) Diabetes Hypertension Cerebrovascular Disease Cardiovascular Disease Malignancy	53% 85% 12% 50% 12%








Figure 3. Comparison of Mean ESAS Symptom Scores at Baseline and at One Year (n=129)




Figure 4. Percentage of Patients with severe ESAS Symptoms (Score 7 to 10) at Baseline and at One Year (n=129)

Limitations

- Retrospective study design
- Symptom scores were analyzed as a group rather than as individuals. Individual patients may
 have experienced clinically significant worsening or improvement of their symptoms but this was
 not captured in the study
- Mean ESAS scores at baseline were lower than those reported in the literature making it difficult to show a statistically significant difference in a patient population with chronic illness facing slow deterioration.
- Study may have been underpowered due to the small sample size and short duration

Conclusions

- After one year, with the exception of depression, there were no statistically significant differences in symptom burden in the HD patients at SPH.
- Further study of a longer duration is needed.









